OTC Markets Group Inc
Change company Symbol lookup
Select an option...
OTCM OTC Markets Group Inc
LCII LCI Industries
COF-K Capital One Financial Corp
ESI Element Solutions Inc
STXB Spirit of Texas Bancshares Inc
ED Consolidated Edison Inc
SNAP Snap Inc
THQ Tekla Healthcare Opportunities Fund
TGIOY Tung Ho Steel Enterprise Corp
RETA Reata Pharmaceuticals Inc
Go

Financials : Capital Markets |
Company profile

OTC Markets Group Inc. organizes securities into three markets based on the quality and quantity of information companies disclose. The Company provides services in three areas: Trading Services, Market Data and Corporate Services. Through its Alternative Trading System (ATS), OTC Link ATS, the Company connects the United States broker-dealers to provide liquidity & execution services for securities on its markets. The Market Data Licensing business line provides investors, traders, institutions, and regulators with a suite of enterprise and user market data licenses. Corporate Services business line includes the OTCQX Best Market (OTCQX), the OTCQB Venture Market (OTCQB) and the Pink Open Market (Pink), and its suite of disclosure and information services. Corporate Service products provide companies with solutions to engage and inform investors.

Closing Price
$50.48
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)
Volume:
185

10-day average volume:
8,667
185

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZY, SLQT and SESN

7:00 pm ET September 9, 2021 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / September 9, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Zymergen Inc. (NASDAQ:ZY)

This lawsuit is on behalf of investors who purchased ZY common stock pursuant and/or traceable to the documents issued in connection with the Company's April 2021 initial public offering.

Lead Plaintiff Deadline: October 4, 2021

During the class period, Zymergen Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) during the qualification process for the Company's optical film product, Hyaline, key customers had encountered technical issues, including product shrinkage and incompatibility with customers' processes; (2) though the qualification process was critical to achieving market acceptance for Hyaline and generating revenue, Zymergen lacked visibility into the qualification process; (3) as a result, the Company overestimated demand for its products; (4) as a result of the foregoing, the Company's product delivery timeline was reasonably likely to be delayed, which in turn would delay revenue generation; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in ZY: https://www.kleinstocklaw.com/pslra-1/zymergen-inc-loss-submission-form?id=19458&from=1

Selectquote, Inc. (NYSE:SLQT)

Class Period: February 8, 2021 - May 11, 2021

Lead Plaintiff Deadline: October 15, 2021

Throughout the class period, Selectquote, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) SelectQuote's 2019 cohort was underperforming; (2) as a result, the Company's financial results would be adversely impacted; and (3) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in SLQT: https://www.kleinstocklaw.com/pslra-1/selectquote-inc-loss-submission-form?id=19458&from=1

Sesen Bio, Inc. (NASDAQ:SESN)

Class Period: December 21, 2020 - August 17, 2021

Lead Plaintiff Deadline: October 18, 2021

According to the complaint, Sesen Bio, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Sesen Bio's clinical trial for its cancer treatment product, Vicineum, had more than 2,000 violations of trial protocol, including 215 classified as "major"; (2) three of Sesen Bio's clinical investigators were found guilty of "serious noncompliance," including "back-dating data"; (3) Sesen Bio had submitted the tainted data in connection with the Biologics License Application ("BLA") for Vicineum; (4) Sesen Bio's clinical trials showed that Vicineum leaked out into the body, leading to side effects including liver failure and liver toxicity, and increasing the risks for fatal, drug-induced liver injury; (5) as a result of the foregoing, the Company's BLA for Vicineum was not likely to be approved; (6) as a result of the foregoing, there was a reasonable likelihood that Sesen Bio would be required to conduct additional trials to support the efficacy and safety of Vicineum; and (7) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Learn about your recoverable losses in SESN: https://www.kleinstocklaw.com/pslra-1/sesen-bio-inc-loss-submission-form?id=19458&from=1

Image: https://www.accesswire.com/users/newswire/images/663467/Klein-Logos_CTA-Logo-3.png

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com.

SOURCE: The Klein Law Firm

View source version on accesswire.com:

https://www.accesswire.com/663467/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-ZY-SLQT-and-SESN

comtex tracking

COMTEX_393082342/2457/2021-09-09T19:00:49

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.